Search PubMedSearch

Biomedical subjects

M Seidman

Publications and source records attributed to M Seidman.

10 recordsLinked to original sources

High level expression of interleukin-1 beta in a recombinant Escherichia coli strain for use in a controlled bioreactor.

A recombinant bacterial strain for the large scale production of human interleukin-1 beta (IL-1 beta) was constructed. The lambda Pr and the tryptophan systems were compared for efficiency of transcription and regulation. The efficiency of IL-1 protein production from these constructs was analyzed. Enhanced protein synthesis was achieved by the fusion of lambda Pr promoter sequences with trp leader sequences which included the trp RBS. A strain (JM101) was selected for use as a host and tested in a one liter bioreactor. A growth and induction regimen was established for use in bioreactors which results in the accumulation of 0.75-0.95 g l-1 of recombinant IL-1.

Base Sequence

Development of a retroviral vector for inducible expression of transforming growth factor beta 1.

A retroviral vector system for the expression of exogenous genes under the control of an inducible promoter was developed. By utilizing this system, the cDNA for human transforming growth factor beta 1 (TGF-beta 1) was inserted into a retroviral vector under the control of an internal mouse metallothionein promoter and introduced via infection into normal rat kidney fibroblasts (NRK-49F) and epithelial cells (NRK-52E), Chinese hamster ovary cells (CHO), and the human monocytic cell line U937. Control of TGF-beta 1 expression, achieved by Cd2+ induction of vector-encoded TGF-beta 1 mRNA, was cell line specific and resulted in a concomitant increase in neutralizable TGF-beta 1 production by the cells. Autocrine stimulation of vector-containing cells by vector-encoded TGF-beta 1 was detected by an increase in soft-agar colony formation of NRK-49F infectants compared with that of the control cells. In addition, the use of a second internal promoter in a retroviral vector of similar design allowed isolation of stable infectants from a cell line (CHO) in which the viral long terminal repeat does not function efficiently.

Animals

A mouse hybrid cell line that supports gene expression from a variety of promoters in amplifiable vectors.

A hybrid cell line was constructed by fusion of mouse L-cells with an NIH3T3 cell line derivative containing a hybrid gene consisting of the mouse immunoglobulin kappa (IgK) variable gene promoter linked to the Escherichia coli gpt gene. Such hybrids grew to a much higher density compared to either of the parental cell lines. The utility of this cell line as a host to express foreign genes was tested by the expression of TGF-beta cDNA using the cytomegalovirus promoter. The vector also contained the human dihydrofolate reductase (DHFR) gene driven by SV40 early promoter, to allow for the amplification of the transfected gene. Initial transformants, selected at 100 nM methotrexate (MTX), were subsequently selected for resistance to a higher concentration of MTX (2 microM). Such clones expressed an increased level of TGF-beta when compared to the initial transformants. Both the initial transformants and the clones with the amplified DHFR gene produced TGF-beta in an acid-activatable precursor form. This mouse hybrid host cell line also allowed the expression of foreign genes cloned in an eukaryotic expression vector with the mouse IgK variable region promoter and human growth hormone as the reporter gene, whereas such vectors did not function in CHO cells. The mouse hybrid cell line was also found to be capable of being used with a broad range of promoters.

Animals

Infection with a TGF-alpha retroviral vector transforms normal mouse mammary epithelial cells but not normal rat fibroblasts.

A cDNA clone of human transforming growth factor alpha (TGF-alpha) was introduced into two different retroviral vectors under the transcriptional control of either the viral LTR, vector 1520, or an internal mouse metallothionein-1 promoter, vector 1522. Infection of normal rat kidney fibroblasts (NRK-49F) and mouse mammary epithelial cells (NOG-8), followed by selection, allowed isolation of individual colonies expressing human TGF-alpha. NRK-49F and NOG-8 1520 infectants conditioned their media with equivalent amounts of TGF-alpha protein but responded differently to autocrine stimulation. NOG-8 infectants formed colonies in soft agar and tumors in nude mice. However, while the NRK-49F infectants proliferated in the presence of transforming growth factor beta (TGF-beta), a response that requires epidermal growth factor (EGF) or TGF-alpha, they exhibited neither anchorage independent growth nor tumorigenicity. NRK-49F cells infected with the 1522 vector produced five-fold more TGF-alpha than the 1520 infectants. Increasing the level of TGF-alpha production by the NRK-49F cells in this way was sufficient to promote agar growth of the cells in the presence of TGF-beta but insufficient to promote tumorigenesis. The EGF receptor level is approximately ten-fold higher on the NOG-8 epithelial cells than on the NRK-49F fibroblast. This fact, in conjunction with the experimental results, suggest that the target cell type and its ability to respond to TGF-alpha is as critical for autocrine stimulation as the amount of growth factor produced by the cells.

Animals

Pseudo-pseudo-Foster Kennedy syndrome.

An 80-year-old woman presented with a classic story and findings of an anterior ischemic optic neuropathy in her left eye. Her right eye had slow and progressive decreased vision, ostensibly secondary to a cataract. However, the right eye showed slight temporal pallor of the optic disc and a superior temporal field defect was found. Her radiologic exam showed a tuberculum sella meningioma extending into the right optic canal compressing the right optic nerve. Two diseases, ischemic optic neuropathy and meningioma, in one patient may be termed a pseudo-pseudo-Foster Kennedy syndrome.

Aged

Two-dimensional electrophoretic display of restriction fragments from genomic DNA.

We have developed a procedure for the resolution of restriction enzyme digests of mammalian genomic DNA in two dimensions. Fragments from a first digestion are separated on a column of purified agarose containing a second restriction enzyme in the absence of the divalent cation required for enzyme activity. After enzyme activation and digestion, the fragments are resolved on an agarose slab gel. We have digested rat genomic DNA and found in the ethidium-stained pattern a variety of features which have not been described previously.

Animals

Silicon metabolism: the basic facts in renal failure.

Silicon levels in plasma and urine have been studied in normal subjects, in chronic renal failure patients, and in regular hemodialysis patients. Plasma levels were elevated in chronic renal failure, and in hemodialysis patients they were three times the control values. Urine silicon excretion is significantly related to creatinine clearance, and to urinary omolality, magnesium and calcium levels. A small amount of residual silicon is found in the hollow fiber artificial kidneys made by some manufacturers. High concentrations of silicon are found in commercial dialysate and pass down a chemical concentration gradient into the blood compartment. It is concluded that silicon is sequestered rapidly in the body during hemodialysis, and that this amounts to 58 g of silicic acid per annum from hemodialysis alone.

Humans

The development of transient SV40 based shuttle vectors for mutagenesis studies: problems and solutions.

Shuttle-vector plasmids would appear to provide a powerful technology for studying mutagenesis in mammalian (including human) cells. Recently, as described in this and other papers in this volume, several shuttle-vector systems have been described and applied. The development of the first shuttle vectors for these purposes was hindered by two major problems. The first of these was the 'poison' sequence present in many pBR322 based vectors. The second was the problem of spontaneous mutagenesis associated with transfection of the plasmids into mammalian cells. Effective solutions for both problems have been devised, and it is now possible to experimentally address a variety of questions concerning mutagenesis and repair in mammalian cells.

DNA Repair